CSPC PHARMA(01093),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01093 CSPC PHARMA

Not Yet Opened 05-19 16:08:20

7.450

-0.130

-1.72%

High7.680	Low7.420	Vol79.37M
Open7.570	D1 Closing7.580	Amplitude3.43%
Mkt Cap85.84B	Tradable Cap85.84B	Total Shares11.52B
T/O594.35M	T/O Rate0.69%	Tradable Shares11.52B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"CSPC PHARMA","latestPrice":7.45,"timestamp":1779178100002,"preClose":7.58,"halted":0,"volume":79367378,"delay":0,"changeRate":-0.0171503957783641,"floatShares":11522000000,"shares":11522000000,"eps":0.3904422070953541,"marketStatus":"Not Yet Opened","change":-0.13,"latestTime":"05-19 16:08:20","open":7.57,"high":7.68,"low":7.42,"amount":594346631,"amplitude":0.034301,"askPrice":7.45,"askSize":1978000,"bidPrice":7.44,"bidSize":428000,"shortable":3,"etf":0,"ttmEps":0.3904422070953541,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779240600000},"marketStatusCode":0,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":7.58,"dividendRate":0.040313,"openAndCloseTimeList":[[1779154200000,1779163200000],[1779166800000,1779177600000]],"volumeRatio":0.931686516067923,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.471,"impliedVolPercentile":0.1579},"requestUrl":"/m/hq/s/01093","defaultTab":"news","newsList":[{"id":"2636886136","title":"CSPC Pharma Secures China Approval for Advanced Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636886136","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636886136?lang=en_us&edition=fundamental","pubTime":"2026-05-19 10:39","pubTimestamp":1779158398,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical  received approval from China's National Medical Products Administration for clinical trials of its SYH2095 tablets for advanced malignant tumors, according to a Monday Hong Kong bourse filing.Shares of the drugmaker were down over 1% in Tuesday morning trade.The drug is a highly selective lysine acetyltransferase 6, or KAT6, inhibitor co-developed with Hangzhou Innogate Pharma, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0008369823.USD","LU1008478684.HKD","BK1521","LU0314109678.HKD","LU2039709279.SGD","IE00B19Z4B17.USD","LU0315179316.USD","BK1191","LU1226288170.HKD","SG9999004220.SGD","LU1328277881.USD","AEIS","LU1960683339.HKD","IE00B66KJ199.SGD","LU1152091168.USD","HK0000165453.HKD","LU0880133367.SGD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU1226287529.USD","LU1226287792.SGD","IE00B031HY20.USD","LU0072913022.USD","LU1226287875.USD","LU0067412154.USD","01093","LU1813983027.USD","BK1515","LU1815336091.USD","IE00BZ08YT58.USD","LU1152091754.HKD","LU1807302812.USD","LU1993786604.SGD","IE00BZ08YS42.EUR","IE0031619046.USD","IE00BZ08YR35.GBP","LU1226288253.USD","BK4157","LU0501845795.SGD","LU0140636845.USD","IE0008368742.USD","LU0757428866.USD","IE00B543WZ88.USD","LU1951186391.HKD","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166973511","title":"CSPC PHARMA (01093): High-Selectivity KAT6 Inhibitor (SYH2095 Tablets) Secures Clinical Trial Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1166973511","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166973511?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:38","pubTimestamp":1779107911,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) announced that the innovative Class 1 chemical drug SYH2095 tablets, co-developed with Hangzhou Yingchuang Pharmaceutical Technology Co., Ltd., has received approval from the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1993786604.SGD","LU0072913022.USD","LU0314109678.HKD","LU1008478684.HKD","LU1960683339.HKD","HK0000165453.HKD","IE00B5MMRT66.SGD","LU1226288253.USD","LU1328277881.USD","LU1226287875.USD","LU0140636845.USD","IE00B031HY20.USD","LU1152091168.USD","BK1521","IE00BZ08YS42.EUR","LU1951186391.HKD","SG9999004220.SGD","LU1807302812.USD","LU0326950275.SGD","BK1191","IE00B543WZ88.USD","LU0501845795.SGD","LU1226287792.SGD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","LU0880133367.SGD","LU2039709279.SGD","IE0008369823.USD","LU1152091754.HKD","LU1813983027.USD","01093","IE0008368742.USD","LU1226288170.HKD","LU0067412154.USD","BK1515","LU0315179316.USD","LU1226287529.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636073763","title":"CSPC KAT6 inhibitor SYH2095 wins China clinical trial approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2636073763","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636073763?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:29","pubTimestamp":1779107377,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical won China clinical trial clearance for SYH2095 tablets, a selective KAT6 inhibitor for advanced malignant tumors, co-developed with Hangzhou Innogate Pharma.The candidate also received US FDA clearance to start clinical trials in April 2026.CSPC said no KAT6-targeting drug has been approved for marketing in China or overseas.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL7RQ8hR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","01093","IE0008368742.USD","LU0501845795.SGD","IE00B031HY20.USD","LU1993786604.SGD","LU1152091168.USD","LU1951186391.HKD","BK1515","LU0140636845.USD","LU1960683339.HKD","HK0000165453.HKD","LU0072913022.USD","LU1226287792.SGD","LU0315179316.USD","BK1191","LU0067412154.USD","LU1226287875.USD","LU1813983027.USD","IE00BZ08YR35.GBP","LU2039709279.SGD","IE00B5MMRT66.SGD","LU0880133367.SGD","LU1008478684.HKD","LU1226288170.HKD","LU1807302812.USD","LU1152091754.HKD","IE00BZ08YT58.USD","LU1328277881.USD","IE0008369823.USD","LU0326950275.SGD","LU0314109678.HKD","IE00B543WZ88.USD","LU1226287529.USD","SG9999004220.SGD","LU1226288253.USD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636073035","title":"CSPC Pharmaceutical - Syh2095 Tablets Obtain Clinical Trial Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2636073035","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636073035?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:29","pubTimestamp":1779107355,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V12Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1152091168.USD","LU1008478684.HKD","LU1226288253.USD","BK1521","IE0008369823.USD","LU1807302812.USD","IE00B5MMRT66.SGD","LU1226287875.USD","IE00BZ08YS42.EUR","LU1226287529.USD","LU1328277881.USD","LU2039709279.SGD","LU0067412154.USD","BK1515","LU1226287792.SGD","LU0140636845.USD","LU0880133367.SGD","HK0000165453.HKD","IE00BZ08YT58.USD","LU1960683339.HKD","LU0072913022.USD","LU0326950275.SGD","IE00B543WZ88.USD","LU0315179316.USD","LU1951186391.HKD","LU0501845795.SGD","IE00BZ08YR35.GBP","IE00B031HY20.USD","IE0008368742.USD","LU1152091754.HKD","LU0314109678.HKD","SG9999004220.SGD","LU1226288170.HKD","LU1813983027.USD","LU1993786604.SGD","01093","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636253300","title":"CSPC Pharmaceutical Group Stock Sheds 2.6% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2636253300","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636253300?lang=en_us&edition=fundamental","pubTime":"2026-05-18 16:32","pubTimestamp":1779093120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. slid 2.6% to 7.58 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.1% to 25675.18.This was the stock's fifth consecutive day of losses.CSPC Pharmaceutical Group Ltd. closed 35% below its 52-week high of HK$11.63, which the company achieved Sept. 9.The stock demonstrated a mixed performance when compared to some of its competitors, as Sino Biopharmaceutical Ltd. fell 1.7%, SSY Group Ltd. fell 1.3%, and United Laboratories International Holdings Ltd. fell 2.8%.Trading volume totaled 67.6 million shares, compared to the 50-day average of 87.4 million shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0315179316.USD","LU1807302812.USD","IE00B031HY20.USD","LU0140636845.USD","LU1226288253.USD","BK1521","LU1226287792.SGD","LU1152091754.HKD","IE0008368742.USD","LU0072913022.USD","LU0501845795.SGD","BK1515","LU1328277881.USD","LU0326950275.SGD","IE00BZ08YR35.GBP","LU1152091168.USD","IE00B543WZ88.USD","HK0000165453.HKD","LU1951186391.HKD","BK1191","IE00B5MMRT66.SGD","LU1813983027.USD","01093","IE00BZ08YS42.EUR","LU1226287529.USD","LU0314109678.HKD","LU1226288170.HKD","IE00BZ08YT58.USD","LU0067412154.USD","SG9999004220.SGD","IE0008369823.USD","LU1226287875.USD","LU2039709279.SGD","LU0880133367.SGD","LU1993786604.SGD","LU1960683339.HKD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156137550","title":"CSPC Pharma Schedules 27 May 2026 Board Meeting to Approve Q1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1156137550","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156137550?lang=en_us&edition=fundamental","pubTime":"2026-05-14 18:43","pubTimestamp":1778755427,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma) will convene a Board of Directors meeting on 27 May 2026 in Hong Kong. The agenda includes approval of the unaudited financial results for the three...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635792385","title":"CSPC Pharmaceutical Group Stock Slips 1.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2635792385","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635792385?lang=en_us&edition=fundamental","pubTime":"2026-05-14 16:33","pubTimestamp":1778747580,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. slid 1.1% to 7.96 Hong Kong dollars , on what proved to be an all-around mediocre trading session for the Hong Kong stock market, with the Hang Seng Index remaining mostly flat at 26389.04.This was the stock's third consecutive day of losses.CSPC Pharmaceutical Group Ltd. closed 32% short of its 52-week high of HK$11.63, which the company achieved Sept. 9.The stock demonstrated a mixed performance when compared to some of its competitors, as Sino Biopharmaceutical Ltd. fell 1.1%, SSY Group Ltd. fell 1.3%, and United Laboratories International Holdings Ltd. fell 0.8%.Trading volume totaled 81.8 million shares, compared to the 50-day average of 87.8 million shares.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287529.USD","BK1521","LU1807302812.USD","LU0501845795.SGD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","LU1152091754.HKD","LU1226287792.SGD","LU1152091168.USD","SG9999004220.SGD","IE00B543WZ88.USD","LU0315179316.USD","LU0326950275.SGD","LU1226288253.USD","LU1813983027.USD","LU0140636845.USD","IE00BZ08YT58.USD","IE00B5MMRT66.SGD","LU1008478684.HKD","IE00B031HY20.USD","BK1191","LU0067412154.USD","HK0000165453.HKD","LU0314109678.HKD","LU1226287875.USD","LU1960683339.HKD","01093","LU0072913022.USD","LU1951186391.HKD","IE0008368742.USD","LU0880133367.SGD","IE0008369823.USD","LU1328277881.USD","BK1515","LU2039709279.SGD","LU1993786604.SGD","LU1226288170.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635766994","title":"Concord Healthcare Completes HK$68 Million Convertible Bond Issue to CSPC Pharma Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2635766994","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635766994?lang=en_us&edition=fundamental","pubTime":"2026-05-14 11:00","pubTimestamp":1778727650,"startTime":"0","endTime":"0","summary":"Concord Healthcare  completed the issuance of HK$68 million convertible bonds to a unit of CSPC Pharmaceutical , according to a Wednesday Hong Kong bourse filing.Shares of the medical services firm were down over 2% in Thursday morning trade.The company issued the 2% convertible bonds due April 2027 to Dragon Merit after all conditions under the placing and subscription agreement were fulfilled.The bonds are convertible into as much as 40 million Hong Kong-listed shares at an initial conversion price of HK$1.70 per share.Concord Healthcare previously said net proceeds of about HK$63.1 million would mainly be used to repay loans and supplement working capital.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0326950275.SGD","BK4585","02453","LU0128526141.USD","BK1209","BK1191","US30Y.BOND","IE00BZ08YT58.USD","IE00B543WZ88.USD","US2Y.BOND","LU0029874061.USD","BK1521","US3Y.BOND","TLTW","LU1813983027.USD","HK0000165453.HKD","CNDA","US10Y.BOND","IE00B031HY20.USD","TLT","IE00BZ08YR35.GBP","IE00B5MMRT66.SGD","LU0067412154.USD","LU1807302812.USD","LU0501845795.SGD","LU1226287529.USD","LU1226287875.USD","LU1152091754.HKD","LU1226288170.HKD","01093","LU0880133367.SGD","LU1008478684.HKD","LU0314109678.HKD","US12M.BOND","US5Y.BOND","XBI","LU0140636845.USD","TMF","BK4581","LU0315179316.USD","LU1152091168.USD","US7Y.BOND","LU1951186391.HKD","LU1993786604.SGD","XLV","LABU","LU1960683339.HKD","US6M.BOND","HCSG","LU2039709279.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188695580","title":"CSPC Pharma Rolls Out 10-Year Share Option Scheme Covering Up to 10% of Issued Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1188695580","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188695580?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:23","pubTimestamp":1778667839,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma, 01093) has adopted a new share option scheme at its annual general meeting on 28 May 2026, subject to Hong Kong Stock Exchange approval. Key parameters...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634296038","title":"CSPC Pharmaceutical Group Stock Slips 1.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2634296038","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634296038?lang=en_us&edition=fundamental","pubTime":"2026-05-12 16:33","pubTimestamp":1778574780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. slid 1.1% to 8.11 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.2% to 26347.91.CSPC Pharmaceutical Group Ltd. closed 30% short of its 52-week high of HK$11.63, which the company reached Sept. 9.The stock demonstrated a mixed performance when compared to some of its competitors, as Sino Biopharmaceutical Ltd. rose 2.1%, SSY Group Ltd. fell 2.1%, and United Laboratories International Holdings Ltd. fell 2.1%.Trading volume totaled 123.5 million shares, compared to the 50-day average of 87.1 million shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU0314109678.HKD","SG9999004220.SGD","IE00BZ08YT58.USD","LU1226287875.USD","IE0008368742.USD","LU1813983027.USD","LU0501845795.SGD","LU1008478684.HKD","LU1152091168.USD","LU2039709279.SGD","LU1807302812.USD","LU1226288253.USD","IE00B543WZ88.USD","LU0880133367.SGD","LU0140636845.USD","LU1226288170.HKD","IE0008369823.USD","LU0326950275.SGD","HK0000165453.HKD","LU1226287792.SGD","LU1328277881.USD","LU1951186391.HKD","LU1993786604.SGD","BK1515","LU0067412154.USD","IE00BZ08YS42.EUR","BK1191","IE00B031HY20.USD","IE00BZ08YR35.GBP","BK1521","LU0072913022.USD","LU1960683339.HKD","LU0315179316.USD","01093","LU1152091754.HKD","LU1226287529.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634837382","title":"CSPC Pharmaceutical's Tumor Drug Gets Breakthrough Therapy Designation in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2634837382","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634837382?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:21","pubTimestamp":1778498514,"startTime":"0","endTime":"0","summary":"CSPC Pharma's  SYS6010 obtained breakthrough therapy designation from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The proposed indication is for use as monotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BZ08YS42.EUR","LU1328277881.USD","LU0326950275.SGD","BK1191","IE00BZ08YT58.USD","IE00B543WZ88.USD","BK1521","LU1813983027.USD","HK0000165453.HKD","IE00B031HY20.USD","IE00BZ08YR35.GBP","IE00B5MMRT66.SGD","LU0067412154.USD","LU1807302812.USD","LU0501845795.SGD","LU1226287529.USD","BK1515","LU1226287875.USD","LU1152091754.HKD","LU0072913022.USD","LU1226288170.HKD","01093","LU0880133367.SGD","LU1008478684.HKD","LU0314109678.HKD","SG9999004220.SGD","LU0140636845.USD","IE0008369823.USD","IE0008368742.USD","LU1226288253.USD","LU0315179316.USD","LU1152091168.USD","LU1951186391.HKD","LU1993786604.SGD","LU1960683339.HKD","LU2039709279.SGD","LU1226287792.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191109408","title":"CSPC PHARMA's SYS 6010 Designated as Breakthrough Therapy in China for Esophageal Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1191109408","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191109408?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:48","pubTimestamp":1778492913,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) announced that its self-developed SYS 6010, a humanized monoclonal antibody-drug conjugate targeting EGFR, has been included again in China's National Medical Products...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","LU0314109678.HKD","LU0315179316.USD","LU1993786604.SGD","LU1226288253.USD","LU0072913022.USD","IE00BZ08YR35.GBP","IE00B5MMRT66.SGD","LU1152091168.USD","LU1960683339.HKD","IE00B543WZ88.USD","LU0880133367.SGD","LU1951186391.HKD","BK1521","LU1226287529.USD","LU1226288170.HKD","IE00BZ08YS42.EUR","BK1191","LU1328277881.USD","BK1515","LU0067412154.USD","LU1226287792.SGD","HK0000165453.HKD","IE0008368742.USD","SG9999004220.SGD","IE00BZ08YT58.USD","LU0140636845.USD","IE0008369823.USD","LU0501845795.SGD","01093","LU1152091754.HKD","IE00B031HY20.USD","LU1807302812.USD","LU1008478684.HKD","LU1813983027.USD","LU0326950275.SGD","LU1226287875.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140868633","title":"CSPC Pharma’s ADC Candidate SYS6010 Wins Second Breakthrough Therapy Designation for Advanced Esophageal Squamous Cell Carcinoma in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1140868633","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140868633?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:44","pubTimestamp":1778492675,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma) announced that its internally developed antibody–drug conjugate (ADC) SYS6010 has received a Breakthrough Therapy Designation (BTD) from China’s...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634402309","title":"CSPC says SYS6010 enters Phase III trial in esophageal squamous cell carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2634402309","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634402309?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:41","pubTimestamp":1778492483,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group flagged SYS6010, an EGFR-targeting antibody-drug conjugate, was again added to China NMPA breakthrough therapy list for use as monotherapy in locally advanced or metastatic esophageal squamous cell carcinoma following failure of platinum chemotherapy, immunotherapy.Clinical study results supporting designation were already generated, with management describing a marked efficacy signal versus current standard options, without disclosing detailed metrics.Phase III confirmatory trial in this indication has been formally launched, positioning program for faster clinical development and regulatory review in China.Broader Phase III development continues in multiple solid tumors, building on a prior breakthrough therapy designation granted in January 2025 for EGFR-mutant, treatment-resistant non-small cell lung cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL2RTqjj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008368742.USD","01093","LU1152091754.HKD","IE00BZ08YT58.USD","IE00B031HY20.USD","LU0072913022.USD","LU1226287529.USD","IE0008369823.USD","SG9999004220.SGD","LU1226288253.USD","HK0000165453.HKD","LU1226287792.SGD","LU1951186391.HKD","LU0501845795.SGD","LU0880133367.SGD","LU1328277881.USD","LU0314109678.HKD","LU1993786604.SGD","LU0315179316.USD","LU0326950275.SGD","IE00B543WZ88.USD","LU0140636845.USD","LU1807302812.USD","BK1515","LU0067412154.USD","IE00BZ08YS42.EUR","BK1191","LU1226287875.USD","LU1226288170.HKD","LU2039709279.SGD","LU1152091168.USD","LU1813983027.USD","LU1960683339.HKD","IE00B5MMRT66.SGD","BK1521","LU1008478684.HKD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634402329","title":"CSPC Pharmaceutical - Sys6010 Granted Breakthrough Therapy Designation in China for Esophageal Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2634402329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634402329?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:41","pubTimestamp":1778492478,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nFWN41O04K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0072913022.USD","LU1813983027.USD","SG9999004220.SGD","IE0008368742.USD","LU0501845795.SGD","LU1226288170.HKD","BK1191","LU1807302812.USD","LU1226287792.SGD","LU1226287875.USD","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","IE0008369823.USD","LU1008478684.HKD","LU1152091168.USD","01093","BK1521","IE00B543WZ88.USD","LU1960683339.HKD","LU1328277881.USD","IE00BZ08YS42.EUR","BK1515","LU1226287529.USD","LU0314109678.HKD","LU1993786604.SGD","LU0880133367.SGD","HK0000165453.HKD","IE00B031HY20.USD","LU2039709279.SGD","LU0067412154.USD","LU1152091754.HKD","LU0326950275.SGD","LU0140636845.USD","LU1226288253.USD","LU0315179316.USD","IE00BZ08YR35.GBP","LU1951186391.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634023214","title":"CSPC Pharmaceutical - Approval Granted by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2634023214","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634023214?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:41","pubTimestamp":1778492478,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nFWN41O04K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1152091168.USD","LU1008478684.HKD","LU1226288253.USD","BK1521","IE0008369823.USD","LU1807302812.USD","IE00B5MMRT66.SGD","LU1226287875.USD","IE00BZ08YS42.EUR","LU1226287529.USD","LU1328277881.USD","LU2039709279.SGD","LU0067412154.USD","BK1515","LU1226287792.SGD","LU0140636845.USD","LU0880133367.SGD","HK0000165453.HKD","IE00BZ08YT58.USD","LU1960683339.HKD","LU0072913022.USD","LU0326950275.SGD","IE00B543WZ88.USD","LU0315179316.USD","LU1951186391.HKD","LU0501845795.SGD","IE00BZ08YR35.GBP","IE00B031HY20.USD","IE0008368742.USD","LU1152091754.HKD","LU0314109678.HKD","SG9999004220.SGD","LU1226288170.HKD","LU1813983027.USD","LU1993786604.SGD","01093","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634402370","title":"CSPC says NMPA grants SYS6010 breakthrough therapy tag for esophageal squamous cell carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2634402370","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634402370?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:41","pubTimestamp":1778492473,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical said NMPA granted Breakthrough Therapy Designation in China for SYS6010 in locally advanced or metastatic esophageal squamous cell carcinoma.Proposed use targets patients who failed prior platinum-based chemotherapy, immunotherapy.Company started Phase III confirmatory trial for this indication; SYS6010 previously received Breakthrough Therapy Designation in January 2025 for EGFR-mutant resistant non-small cell lung cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 11, 2026, and is solely responsible for the information containe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL4vSJF2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1807302812.USD","01093","HK0000165453.HKD","LU0501845795.SGD","LU0315179316.USD","LU0880133367.SGD","IE0008369823.USD","LU1152091168.USD","BK1515","LU1152091754.HKD","BK1191","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","LU1951186391.HKD","SG9999004220.SGD","LU0314109678.HKD","LU1226288253.USD","BK1521","LU1226288170.HKD","IE00BZ08YS42.EUR","LU1328277881.USD","LU1993786604.SGD","LU0072913022.USD","IE00B031HY20.USD","LU1226287792.SGD","LU0326950275.SGD","LU0067412154.USD","IE00B5MMRT66.SGD","LU0140636845.USD","LU1008478684.HKD","IE0008368742.USD","LU1813983027.USD","LU2039709279.SGD","LU1226287529.USD","IE00B543WZ88.USD","LU1960683339.HKD","LU1226287875.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161500414","title":"Citigroup: Fundamentals of China's Healthcare Sector Show Sustained Improvement, Top Picks Include WuXi AppTec (02359)","url":"https://stock-news.laohu8.com/highlight/detail?id=1161500414","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161500414?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:00","pubTimestamp":1778490036,"startTime":"0","endTime":"0","summary":"Citigroup has released a research report stating that the past fiscal year and the first-quarter earnings season confirm a sustained improvement in the fundamentals of China's healthcare industry....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1668664300.SGD","02269","IE0008368742.USD","LU2417539215.USD","LU0455707207.USD","IE00B031HY20.USD","LU0708995583.HKD","IE00B5MMRT66.SGD","LU0072913022.USD","SG9999002562.SGD","BK1583","LU0310800965.SGD","LU0052750758.USD","LU0572944931.SGD","LU0072461881.USD","IE00BZ08YS42.EUR","LU2360032135.SGD","LU2488822045.USD","LU1993786604.SGD","LU2097828474.EUR","LU0516422440.USD","LU0130517989.USD","LU0516422366.SGD","LU1152091168.USD","LU2045819591.USD","LU2242644610.SGD","01801","LU0516423174.USD","LU1794554557.SGD","LU0130102774.USD","LU1791807156.HKD","BK1191","BK1515","LU2125154935.USD","BK4588","LU0051755006.USD","LU1152091754.HKD","LU0588546209.SGD","01672","IE00BZ08YT58.USD","LU0359201612.USD","LU0823426308.USD","LU1303224171.USD","SG9999004220.SGD","LU1719994722.HKD","LU2125910500.SGD","LU2495084118.USD","LU1244550494.USD","LU0140636845.USD","LU0501845795.SGD","LU0456846285.SGD","LU1808992512.USD","LU1226288253.USD","01276","C","LU3063872942.SGD","LU0098860793.USD","LU1251922891.USD","LU0348767384.USD","LU0106831901.USD","LU2097828557.USD","LU0516423091.SGD","LU0203347892.USD","LU1162221912.USD","LU1242518857.USD","BK1521","LU0320764599.SGD","LU0052756011.USD","LU1969619763.USD","LU0819121731.USD","02359","BK4207","BK4566","LU1720050803.USD","LU0043850808.USD","IE00BSNM7G36.USD","LU0417516902.SGD","LU1997245094.SGD","LU0320765646.SGD","HK0000165453.HKD","LU1023057109.AUD","LU1960683339.HKD","BK1161","LU1244550221.USD","BK1576","LU0314109678.HKD","LU0359202008.SGD","LU1506573853.SGD","LU1951186391.HKD","LU2125154778.USD","LU0456842615.SGD","LU0170899867.USD","LU0307460666.USD","LU1807302812.USD","LU1880383366.USD","LU1934453819.USD","BK1574","BK4585","SG9999002463.SGD","LU0314106906.USD","LU1997245177.USD","LU1226287792.SGD","LU0348766576.USD","LU1244550577.SGD","LU0067412154.USD","LU1226287875.USD","IE0008369823.USD","LU0359201885.HKD","BK4504","LU1008478684.HKD","LU2039709279.SGD","LU0477156953.USD","BK0216","LU0128525689.USD","LU2097828631.EUR","BK4534","LU1242518931.SGD","LU1201861249.SGD","LU0417516738.SGD","BK4559","LU2236285917.USD","LU2097828805.USD","LU0456827905.SGD","LU0980610538.SGD","LU2328871848.SGD","LU1267930227.SGD","LU2097828714.EUR","LU0162691827.USD","LU0823426480.USD","LU1328277881.USD","LU0315179316.USD","LU1770034418.SGD","LU1997244956.HKD","BK1141","603259","LU0502904849.HKD","LU1046422090.SGD","LU2462157665.USD","LU0203345920.USD","LU0856984785.SGD","LU1979443071.USD","LU0327786744.USD","LU1688375341.USD","BK1610","LU0880133367.SGD","LU0181495838.USD","BK1589","LU0648001328.SGD","LU0326950275.SGD","LU0348735423.USD","LU0348825331.USD","LU0516422952.EUR","IE00BZ08YR35.GBP","LU2543165471.USD","LU1226288170.HKD","LU1813983027.USD","IE00B543WZ88.USD","01093","LU1226287529.USD","LU0039217434.USD","LU2456880835.USD","LU1366192091.USD","IE00B0JY6N72.USD","LU0979878070.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634422176","title":"Concord Healthcare prices HK$ 68 million 2% convertible bonds due 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2634422176","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634422176?lang=en_us&edition=fundamental","pubTime":"2026-05-11 08:01","pubTimestamp":1778457709,"startTime":"0","endTime":"0","summary":"Concord Healthcare Group set to issue HK$ 68 million of 2% convertible bonds due 2027 via placing and subscription agreement signed May 10.Subscriber Dragon Merit Holdings, wholly owned by CSPC Pharmaceutical Group, to subscribe at 100% of principal on closing date May 13.Bonds convertible into H shares at initial conversion price HK$ 1.7, implying up to 40,000,000 new H shares on full conversion.Net proceeds estimated at about HK$ 63.1 million, earmarked mainly for loan repayment, remainder for working capital.No listing planned for bonds; listing application to be made for conversion shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Concord Healthcare Group Co. Ltd. published the original content used to generate this news brief","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8M3vbJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1152091168.USD","LU1226287875.USD","IE00B543WZ88.USD","LU1226287792.SGD","LU1226288170.HKD","BK1515","LU1807302812.USD","01093","BK1209","IE0008369823.USD","LU1813983027.USD","IE00BZ08YR35.GBP","LU1152091754.HKD","BK1521","BK1191","LU0501845795.SGD","IE00BZ08YT58.USD","IE00B5MMRT66.SGD","IE00B031HY20.USD","LU1960683339.HKD","LU2039709279.SGD","HK0000165453.HKD","LU0072913022.USD","LU1226287529.USD","SG9999004220.SGD","LU0140636845.USD","LU0314109678.HKD","LU1993786604.SGD","LU1951186391.HKD","LU0315179316.USD","IE0008368742.USD","02453","LU0326950275.SGD","LU1008478684.HKD","IE00BZ08YS42.EUR","LU0880133367.SGD","LU1226288253.USD","LU1328277881.USD","LU0067412154.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633198323","title":"Why CSPC Pharmaceutical Group's (HKG:1093) Shaky Earnings Are Just The Beginning Of Its Problems","url":"https://stock-news.laohu8.com/highlight/detail?id=2633198323","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633198323?lang=en_us&edition=fundamental","pubTime":"2026-05-07 08:49","pubTimestamp":1778114993,"startTime":"0","endTime":"0","summary":"Last week's earnings announcement from CSPC Pharmaceutical Group Limited ( HKG:1093 ) was disappointing to investors...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/why-cspc-pharmaceutical-groups-hkg1093-shaky-earnings-are-ju","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/why-cspc-pharmaceutical-groups-hkg1093-shaky-earnings-are-ju","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":-0.0814},{"period":"1month","weight":-0.1685},{"period":"3month","weight":-0.2732},{"period":"6month","weight":-0.035},{"period":"1year","weight":0.2898},{"period":"ytd","weight":-0.1163}],"compareEarnings":[{"period":"1week","weight":-0.0209},{"period":"1month","weight":-0.0139},{"period":"3month","weight":-0.034},{"period":"6month","weight":-0.0015},{"period":"1year","weight":0.1057},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.009625},{"month":2,"riseRate":0.75,"avgChangeRate":0.094687},{"month":3,"riseRate":0.46875,"avgChangeRate":0.017323},{"month":4,"riseRate":0.59375,"avgChangeRate":0.057765},{"month":5,"riseRate":0.59375,"avgChangeRate":0.042385},{"month":6,"riseRate":0.322581,"avgChangeRate":0.003636},{"month":7,"riseRate":0.375,"avgChangeRate":0.009082},{"month":8,"riseRate":0.4375,"avgChangeRate":0.010009},{"month":9,"riseRate":0.5,"avgChangeRate":0.000153},{"month":10,"riseRate":0.5625,"avgChangeRate":0.010484},{"month":11,"riseRate":0.46875,"avgChangeRate":0.00638},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013271}],"exchange":"SEHK","name":"CSPC PHARMA","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CSPC PHARMA(01093),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CSPC PHARMA(01093) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CSPC PHARMA,01093,CSPC PHARMA股票,CSPC PHARMA股票老虎,CSPC PHARMA股票老虎国际,CSPC PHARMA行情,CSPC PHARMA股票行情,CSPC PHARMA股价,CSPC PHARMA股市,CSPC PHARMA股票价格,CSPC PHARMA股票交易,CSPC PHARMA股票购买,CSPC PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CSPC PHARMA(01093),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CSPC PHARMA(01093) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}